Chardan Capital Maintains Buy on Tenaya Therapeutics, Lowers Price Target to $8
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
Chardan Capital analyst Geulah Livshits maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and lowers the price target from $9 to $8.
Chardan Capital analyst Geulah Livshits maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and lowers the price target from $9 to $8.